Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 5, 2021
Reporting Period: Single event date (October 5, 2021)
Business Context: The filing reports a specific corporate event regarding the release of securities from a lock-up agreement to facilitate a private transaction.
Key Financial Metrics
This filing does not contain financial performance data. The following metrics are not provided in the source text:
- Revenue
- Profit
- Cash Flow
- Margins
- Debt
- Liquidity
Material Changes
The filing details a material change in the status of securities held by an executive officer:
- Event: Release of 200,000 shares of common stock and 150,000 warrants from a Lock-Up Agreement.
- Beneficial Owner: Dr. Bankole Johnson, Chief Medical Officer.
- Warrant Terms: Exercisable at $6.25 per share; expiring July 31, 2023.
- Purpose: To permit the sale of these securities to BesSpoke Growth Partners, Inc. in a private transaction.
- Agreement Reference: Lock-Up Agreement dated December 12, 2019, as amended.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the disclosure of the transaction itself. No unusual items or contingencies are described in this document.
Investor Verification Checklist
- Verify the terms of the private transaction between Dr. Johnson and BesSpoke Growth Partners, Inc.
- Confirm the impact of this release on the company's total outstanding share count and warrant pool.
- Review the original Lock-Up Agreement dated December 12, 2019, to understand the conditions under which the release was granted.
- Check for any subsequent filings regarding the actual sale price or settlement of the transaction.